Prostatic Cancer Chemotherapy

  • F. M. Torti
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 85)

Abstract

Each year, 50,000 new cases of prostatic carcinoma are diagnosed in the United States. It is estimated that 85% have regional or distant metastatic disease at the time of diagnosis. Thus, the management of metastatic disease is a major therapeutic problem for the urologist, radiation therapist, and medical oncologist.

Keywords

Estrogen Testosterone Methotrexate Vincristine Mitomycin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Al-Sarraf M (1980) Combination of Cytoxan, adriamycin and cis-platinum (CAP) in patients with advanced prostatic cancer. Proc AACR and ASCO 21: 198Google Scholar
  2. 2.
    Andersson L, Edsmyr F, Jonsson G, Konyves I (1977) Estramustine phosphate therapy in carcinoma of the prostate. In: Grundmann E, Vahlensieck W (eds) Tumors of the male genital system. Springer, Berlin Heidelberg New York, pp 73–77 (Recent Results in Cancer Research, vol 60)CrossRefGoogle Scholar
  3. 3.
    Arduino L, Bailar JL, Becker L et al. (1967) Carcinoma of the prostate treatment comparison. J Urol 98:516–522Google Scholar
  4. 4.
    Arduino L, Bailar JL, Becker L, et al. (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011–1017Google Scholar
  5. 5.
    Byar DP (1977) VACURG studies on prostatic carcinoma. In: Tannenbaum M (ed) Urologic pathology: the prostate, Lea and Febiger, Philadelphia, p 241Google Scholar
  6. 6.
    Chlebowski RT, Hestorff R, Sardoff L, Weiner J, Bateman JR (1978) Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fiuorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trial. Cancer 42:2546–2552PubMedCrossRefGoogle Scholar
  7. 7.
    DeWys WD, Bauer M, Colsky J, Cooper RA, Creech R, Carbone PP (1977) Comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer-Progress report. Cancer Treat Rep 61:325–328PubMedGoogle Scholar
  8. 8.
    DeWys DW, Begg CB (1978) Comparison of adriamycin (ADRIA) and 5-fluorouracil (5 FU) in advanced prostatic cancer. Proc AACR and ASCO 19:331Google Scholar
  9. 9.
    Eagan RT, Hahn RG, Myers RP (1976) Adriamycin (NSC 127127) versus 5-fluorouracil (NSC 19893) and cyclophosphamide (NSC 26271) in the treatment of metastatic prostate cancer. Cancer Treat Rep 60:115–117PubMedGoogle Scholar
  10. 10.
    Fossa SD, Miller A (1976) Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol 115:406–408PubMedGoogle Scholar
  11. 11.
    Fritjofsson A, Norlen BJ, Hogberg B, Rajalakshmi, Cekan SZ, Doczfalusy E (1981) Hormonal effects of different doses of estramustine phosphate (estracyT) in patients with prostatic carcinoma. Scand J Urol Nephrol 15:37–44PubMedCrossRefGoogle Scholar
  12. 12.
    Gagnon JF, Moss WT, Stevens KR (1979) Pre-estrogen breast irradiation for patients with carcinoma of the prostate: A critical review. J Urol 121:182–184PubMedGoogle Scholar
  13. 13.
    Ihde DC, Bunn PA, Cohen MH, Dunnick NR, Eddy JL, Minna JD (1980) Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Cancer 45:1300–1310PubMedCrossRefGoogle Scholar
  14. 14.
    Izbicki RM, Amer MH, Al-Sarraf M (1979) Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma: A Phase II study. Cancer Treat Rep 63:999–1001PubMedGoogle Scholar
  15. 15.
    Izbicki RM, Amer M, Al-Sarraf M (1978) A prospective study of a combination of adriamycin and Cytoxan in the treatment of patients with advanced prostatic cancer. Proc Am Assoc Cancer Res Am Soc Clin Oncol 19:312 (abstract)Google Scholar
  16. 16.
    Lindberg B (1972) Treatment of rapidly progressing prostatic carcinoma with estracyt. J Urol 108:303–306PubMedGoogle Scholar
  17. 17.
    Leoning SA, Scott WW, deKernion J, Gibbons RP, Johnson DE, Pontes JE, Prout GR, Schmidt JD, Soloway MS, Chu TM, Gaeta JF, Slack NH, Murphy GP (1981) A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate. J Urol 125:812–816Google Scholar
  18. 18.
    Logothetis C, von Eschenbach A, Samuels M, Haynie TP, Johnson DE (1981) Doxorubicin, mitomycin-C, 5-fluorouracil (DMF) in the therapy of hormonal resistant adenocarcinoma of the prostate. Proc AACR and ASCO 22:462Google Scholar
  19. 19.
    Logothetis CJ, von Eschenbach AC, Samuels ML, Trindade A, Johnson DE (1982) Doxorubicin, Mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report. Cancer Treat Rep 66:57–63PubMedGoogle Scholar
  20. 20.
    Madajewicz S, Catane R, Mittelman A, Wajsman Z, Murphy GP (1980) Chemotherapy of advanced, hormonally resistant prostatic carcinoma. Oncology 37:53–56PubMedCrossRefGoogle Scholar
  21. 21.
    Merrin C (1978) Treatment of advanced carcinoma of the prostate (stage D) with infusion of cis-diamminedichloroplatinum (II NSC 119875): a pilot study. J Urol 119:522–524PubMedGoogle Scholar
  22. 22.
    Merrin CE, Beckley A (1979) The treatment of estrogen-resistant stage D carcinoma of the prostate with cis-diamminedichloroplatinum. Urology 13:267–272PubMedCrossRefGoogle Scholar
  23. 23.
    Merrin C, Etra W, Wajsman Z, Baumgartner G, Murphy G (1976) Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide, and adriamycin. J Urol 115:86–88PubMedGoogle Scholar
  24. 24.
    Mittelman A, Shukla SK, Welvaar TK, Murphy GP (1975) Oral estramustine phosphate in the treatment of advanced stage D carcinoma of the prostate. Cancer Chemother Rep 59:219–223PubMedGoogle Scholar
  25. 25.
    Mittelman A, Shukla SK, Murphy GP (1976) Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate. J Urol 115:409–412PubMedGoogle Scholar
  26. 26.
    Murphy GP, Gibbons RP, Johnson DE et al. (1979) The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. J Urol 121:763–765PubMedGoogle Scholar
  27. 27.
    Murphy GP, Gibbons RP, Johnson DE (1977) A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation. J Urol 118:288–291PubMedGoogle Scholar
  28. 28.
    Muss HB, Howard V, Richards F, White DR, Jackson DV, Cooper MR, Stuart JJ, Resnick MI, Brodkin R, Spurr CL (1981) Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. Cancer 47:1949–1953PubMedCrossRefGoogle Scholar
  29. 29.
    Nagel R, Kollin SP (1976) Treatment of advanced carcinoma of the prostate with estracyt. In: Marberger H (ed) Prostatic disease. Liss, New York, pp 267–283Google Scholar
  30. 30.
    Nagel R, Kollin CP (1977) Treatment of advanced carcinoma of the prostate with estramustine phosphate. Br J Urol 49:73–79PubMedCrossRefGoogle Scholar
  31. 31.
    O’Bryan RM, Baker LH, Gottlieb JE et al. (1977) Dose response evaluation of adriamycin in human neoplasia. Cancer 39:1940–1948PubMedCrossRefGoogle Scholar
  32. 32.
    Perloff M, Ohnuma T, Holland JF, Kennedy BJ, Mills RC (1977) Adriamycin (ADM) and diamminedichloroplatinum (DDP) in advanced prostatic carcinoma (PC). Proc Am Assoc Cancer Res Am Soc Clin Oncol 18: 333 (abstract)Google Scholar
  33. 33.
    Presant CA, Van Amburg A, Klahr C, Metter GE (1980) Chemotherapy of advanced prostatic cancer with adriamycin, BCNU, and cyclophosphamide. Cancer 46: 2389–2392PubMedCrossRefGoogle Scholar
  34. 34.
    Schmidt JD, Scott WW, Gibbons RP et al. (1979) Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide inrelapsing patients with advanced carcinoma of the prostate. J Urol 121:185–189PubMedGoogle Scholar
  35. 35.
    Schmidt JD, Johnson DE, Scott WW, Gibbons RP, Prout GR, Murphy GP (1976) Chemotherapy of advanced prostatic cancer: evaluation of response parameters. Urology 7:602–610PubMedCrossRefGoogle Scholar
  36. 36.
    Scott W, Johnson DE, Schmidt JE et al. (1976) Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study. J Urol 114:909–911Google Scholar
  37. 37.
    Scott WW, Gibbons RP, Johnson DE et al. (1975) Comparison of 5-fluorouracil (NSC-019893) and cyclophosphamide (NSC-026271) in patients with advanced carcinoma of the prostate. Cancer Chemother Rep 59:195–201Google Scholar
  38. 38.
    Scott WW, Gibbons RP, Johnson DE et al. (1976) The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J Urol 116:211–213PubMedGoogle Scholar
  39. 39.
    Smalley RV, Bartolucci AA, Hemstreet G, Hester M (1981) A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and or 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 125:191–195PubMedGoogle Scholar
  40. 40.
    Soloway MS, de Kernion JB, Gibbons RP, Johnson DE, Leoning SA, Pontes JE, Prout GR, Schmidt JD, Scott WW, Chu TM, Gaeta JF, Slack NH, Murphy GP (1981) Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced hormone refractory, previously irradiated carcinoma of the prostate. J Urol 125:664–667PubMedGoogle Scholar
  41. 41.
    Straus MJ, Parmelee J, Olsson C, De Vere White R (1978) Cytoxan, adriamycin and methotrexate (CAM) therapy of stage D prostate cancer. Proc Am Assoc Cancer Res Am Soc Clin Oncol 19:314 (abstract)Google Scholar
  42. 42.
    Torti FM, Carter SK (1980) The chemotherapy of prostatic adenocarcinoma. Ann Intern Med 92:681–689PubMedGoogle Scholar
  43. 43.
    Yagoda A, Watson RC, Natale RB, Barzell W, Sogani P, Grabstald H, Whitmore WF (1979) A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 44:1553–1562PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • F. M. Torti
    • 1
  1. 1.Division of Medical OncologyStanford University Medical CenterPalo AltoUSA

Personalised recommendations